Nathan A. Pennell MD, PhD, FASCO (n8pennell)

1.

As #TTLC23 comes to a close, check out the new @IASLC Atlas of Molecular Testing for Targeted Therapy in Lung Can… twitter.com/i/web/status/1…

Retweet of status by @JessicaJLinMD

@TumorBoardTues 3/17 #TumorBoardTuesday #LCSM
Mini tweetorial 1

EGFR mutations

≈15% of🫁adenocarcinomas
More… twitter.com/i/web/status/1…

NCAA RECORD

UNC's rout of Marquette was the largest ever in an 8 vs. 9 game #MarchMadness pic.twitter.com/C9prbD02b5

Retweet of status by @MarchMadnessMBB

FDA #VRBPAC voted 17-0 (1 abstention) in favor of issuing an EUA for Pfizer’s #COVID19 vaccine for 5-11 year olds

Retweet of status by @DataDrivenMD

Great talk Max
Much progress for our #lungcancer patients. Insurances need to approve NGS profiling of non-metas… twitter.com/i/web/status/1…

Retweet of status by @HenningWillers

#ASCO21 Post-Plenary Sessions kick off this week! Live, 30min Q&A panels for new Qs ones not addressed in Plenary… twitter.com/i/web/status/1…

Retweet of status by @IshwariaMD

What everyone else sees in the snow

What I see pic.twitter.com/k5QpRyGr6G

Retweet of status by @gelliottmorris

Recent FDA approvals for #NSCLC
May 6 - Capmatinib - METex14
May 9 - Selpercatinib - RET-fusion
May 18 - Atezoli… twitter.com/i/web/status/1…

Retweet of status by @VivekSubbiah

FDA approves selpercatinib for RET-dependent lung and thyroid cancers!! Line agnostic. So many patients and rese… twitter.com/i/web/status/1…

Retweet of status by @alexdrilon

fakhright @fakhright

astaghfirullah peng.krim guaaaaaaaa..............a *salto sambil solat*